Search results
Search for "carboxamide" in Full Text gives 111 result(s) in Beilstein Journal of Organic Chemistry.
Access to pyrrolo-pyridines by gold-catalyzed hydroarylation of pyrroles tethered to terminal alkynes
- Elena Borsini,
- Gianluigi Broggini,
- Andrea Fasana,
- Chiara Baldassarri,
- Angelo M. Manzo and
- Alcide D. Perboni
Beilstein J. Org. Chem. 2011, 7, 1468–1474, doi:10.3762/bjoc.7.170
- either from direct cyclization or from a formal rearrangement of the carboxamide group. Terminal alkynes are essential to achieve bicyclic pyrrolo-fused pyridinones by a 6-exo-dig process, while the presence of a phenyl group at the C–C triple bond promotes the 7-endo-dig cyclization giving pyrrolo
- . Cyclization reactions of pyrrole-carboxamides A solution of the appropriate pyrrole-carboxamide (2 mmol) was stirred, under an argon atmosphere, with AuCl3 (0.01 mmol) in 30 mL of an appropriate solvent (see Table 3 and Table 4 for solvents, temperatures and times). At the end of the reaction, the solvent was
Graphical Abstract
Scheme 1: Pd-catalyzed cyclization of N-allyl-pyrrole-2-carboxamides.
Figure 1: Significant relationships among hydrogen and carbon atoms arising from 2D-NMR studies to determine ...
Scheme 2: Proposed mechanism for the formation of the six-membered products.
NMR studies of anion-induced conformational changes in diindolylureas and diindolylthioureas
- Damjan Makuc,
- Jennifer R. Hiscock,
- Mark E. Light,
- Philip A. Gale and
- Janez Plavec
Beilstein J. Org. Chem. 2011, 7, 1205–1214, doi:10.3762/bjoc.7.140
- -indole-2-carboxamide (0.27 g, 1.07 mM) with 7-isothiocyanato-N-phenyl-1H-indole-2-carboxamide (0.31 g, 1.07 mM) in pyridine in 27% yield (see Supporting Information File 1 for details). Structural features and NMR chemical shifts The conformational properties of diindolylureas and diindolylthioureas 1–4
- are spatially close and the C2α carbonyl group is oriented towards the indole H1 proton. NOE enhancements between H2β and H3 protons were observed also in the 3·AcO− and 3·BzO− complexes, which suggests that the orientation of the carboxamide group along the C2–C2α bond is retained in 3 upon addition
Graphical Abstract
Figure 1: Anion receptors 1–4 together with their atomic numbering scheme.
Figure 2: 1H NMR spectra of 1 in the absence of anions (a) and upon addition of one equivalent of the followi...
Figure 3: Three representative conformational families of rotamers of 1. Notations refer to the orientations ...
Figure 4: NOE enhancements of 1 in the absence of anions (a) and upon addition of one equivalent of acetate a...
Figure 5: Surface plot of the relative potential energy of 1 as a function of the two constitutive [C6–C7–N7α...
Figure 6: Freely optimized structure at the B3LYP/6-311+G(d,p) level of theory and side view showing deviatio...
Figure 7: 1H NMR chemical shift changes, Δδ = δ (in the presence of anions) – δ (in the absence of anions), i...
Figure 8: Freely optimized structures at the B3LYP/6-311+G(d,p) level of theory and side view showing deviati...
Figure 9: Conformational preferences and proposed binding mode for the 3·AcO− 1:1 complex.
An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
- Marcus Baumann,
- Ian R. Baxendale,
- Steven V. Ley and
- Nikzad Nikbin
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
- as T-cells and macrophages followed by viral fusion and entry into white blood cells. Maraviroc blocks this pathway by acting as an antagonist for the CCR-5 receptor hence disrupting HIV life cycle. The structural features of this molecule are a geminal difluorocyclohexyl carboxamide which is linked
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Approaches towards the synthesis of 5-aminopyrazoles
- Ranjana Aggarwal,
- Vinod Kumar,
- Rajiv Kumar and
- Shiv P. Singh
Beilstein J. Org. Chem. 2011, 7, 179–197, doi:10.3762/bjoc.7.25
- reviewed in two books published in 1964 [5] and in 1967 [6]. Structurally simple 5-amino-1-tert-butylpyrazole-4-carboxamide I was found to inhibit p56 Lck [7] (Figure 1). 5-Amino-1-(4-methylphenyl) pyrazole II has been tested as an NPY5 antagonist [8]. 5-Amino-4-benzoyl-3-methylthio-1-(2,4,6
- al. [71] have reported that the reaction of α-cyano-β-dimethylaminocrotonamide (103) with hydrazine hydrate yields 5-amino-3-methylpyrazole-4-carboxamide (104). The reaction proceeds by loss of dimethylamine in first step followed by cyclization via nucleophilic attack on cyano group (Scheme 29). 3
- -heteroaryl-3-methyl/aryl-4-cyanopyrazoles. Synthesis of 5-amino-3-methylpyrazole-4-carboxamide. Synthesis of 4-acylamino-3(5)-amino-5(3)-arylsulfanylpyrazoles. Synthesis of 5-amino-1-aryl-4-diethoxyphosphoryl-3-halomethylpyrazoles. Synthesis of substituted 5-amino-3-trifluoromethylpyrazoles 114 and 118
Graphical Abstract
Figure 1: Pharmacologically active 5-aminopyrazoles.
Scheme 1: General equation for the condensation of β-ketonitriles with hydrazines.
Scheme 2: Reaction of hydrazinoheterocycles with α-phenyl-β-cyanoketones (4).
Scheme 3: Condensation of cyanoacetaldehyde (7) with hydrazines.
Scheme 4: Synthesis of 5-aminopyrazoles and their sulfonamide derivatives.
Scheme 5: Synthesis of 5-aminopyrazoles, containing a cyclohexylmethyl- or phenylmethyl- sulfonamido group at...
Scheme 6: Regioselective synthesis of 3-amino-2-alkyl (or aryl) thieno[3,4-c]pyrazoles 19.
Scheme 7: Solid supported synthesis of 5-aminopyrazoles.
Scheme 8: Synthesis of 5-aminopyrazoles from resin supported enamine nitrile 25 as the starting material.
Scheme 9: Two-step “catch and release” solid-phase synthesis of 3,4,5-trisubstituted pyrazoles.
Scheme 10: Synthesis of pyrazolo[5,1-d][1,2,3,5]tetrazine-4(3H)-ones.
Scheme 11: Synthesis of the 5,5-ring system, imidazo[1,2-b]pyrazol-2-ones.
Scheme 12: Synthesis of 5-amino-3-(pyrrol-2-yl)pyrazole-4-carbonitrile.
Scheme 13: Synthesis of N-(1,3-diaryl-1H-pyrazol-5-yl)benzamide.
Scheme 14: Synthesis of 3,7-bis(arylazo)-6-methyl-2-phenyl-1H-imidazo[1,2-b]pyrazoles.
Scheme 15: Synthesis of 3,5-diaminopyrazole.
Scheme 16: Synthesis of 5-amino-4-cyanopyrazole and 5-amino-3-hydrazinopyrazole.
Scheme 17: Synthesis of 3,5-diaminopyrazoles with substituted malononitriles.
Scheme 18: Synthesis of 3,5-diamino-4-oximinopyrazole.
Scheme 19: Synthesis of 4-arylazo-3,5-diaminopyrazoles.
Scheme 20: Synthesis of 3- or 5-amino-4-cyanopyrazoles.
Scheme 21: Synthesis of triazenopyrazoles.
Scheme 22: Synthesis of 5(3)-aminopyrazoles.
Scheme 23: Synthesis of 3-substituted 5-amino-4-cyanopyrazoles.
Scheme 24: Synthesis of 2-{[(1-acetyl-4-cyano-1H-pyrazol-5-yl)amino]methylene}malononitrile.
Scheme 25: Synthesis of 5-aminopyrazole carbodithioates and 5-amino-3-arylamino-1-phenylpyrazole-4-carboxamide...
Scheme 26: Synthesis of 5-amino-4-cyanopyrazoles.
Scheme 27: Synthesis of thiazolylpyrazoles.
Scheme 28: Synthesis of 5-amino-1-heteroaryl-3-methyl/aryl-4-cyanopyrazoles.
Scheme 29: Synthesis of 5-amino-3-methylpyrazole-4-carboxamide.
Scheme 30: Synthesis of 4-acylamino-3(5)-amino-5(3)-arylsulfanylpyrazoles.
Scheme 31: Synthesis of 5-amino-1-aryl-4-diethoxyphosphoryl-3-halomethylpyrazoles.
Scheme 32: Synthesis of substituted 5-amino-3-trifluoromethylpyrazoles 114 and 118.
Scheme 33: Solid-support synthesis of 5-N-alkylamino and 5-N-arylaminopyrazoles.
Scheme 34: Synthesis of 5-amino-1-cyanoacetyl-3-phenyl-1H-pyrazole.
Scheme 35: Synthesis of 3-substituted 5-amino-1-aryl-4-(benzothiazol-2-yl)pyrazoles.
Scheme 36: Synthesis of 5-amino-4-carbethoxy-3-methyl-1-(4-sulfamoylphenyl)pyrazole.
Scheme 37: Synthesis of inhibitors of hsp27-phosphorylation and TNFa-release.
Scheme 38: Synthesis of the diglycylpyrazole 142.
Scheme 39: Synthesis of 5-amino-1-aryl-4-benzoylpyrazole derivatives.
Scheme 40: Synthesis of 4-benzoyl-3,5-diamino-1-(2-cyanoethyl)pyrazole.
Scheme 41: Synthesis of the 5-aminopyrazole derivative 150.
Scheme 42: Synthesis of 3,5-diaminopyrazoles 153.
Scheme 43: Synthesis of 5-aminopyrazoles derivatives 155 via lithiated intermediates.
Scheme 44: Synthesis of 5-amino-4-(1,2,4-oxadiazol-5-yl)-pyrazoles 157.
Scheme 45: Synthesis of a 5-aminopyrazole with anticonvulsant activity.
Scheme 46: Synthesis of tetrasubstituted 5-aminopyrazole derivatives.
Scheme 47: Synthesis of substituted 5-aminopyrazoles from hydrazonoyl halides.
Scheme 48: Synthesis of 3-amino-5-phenylpyrazoles from isothiazoles.
Scheme 49: Synthesis of 5-aminopyrazoles via ring transformation.
A new fluorescent chemosensor for fluoride anion based on a pyrrole–isoxazole derivative
- Zhipei Yang,
- Kai Zhang,
- Fangbin Gong,
- Shayu Li,
- Jun Chen,
- Jin Shi Ma,
- Lyubov N. Sobenina,
- Albina I. Mikhaleva,
- Guoqiang Yang and
- Boris A. Trofimov
Beilstein J. Org. Chem. 2011, 7, 46–52, doi:10.3762/bjoc.7.8
- recognition and sensing purposes in aprotic solvents. We present here a new example of a receptor, 3-amino-5-(4,5,6,7-tetrahydro-1H-indol-2-yl)isoxazole-4-carboxamide (receptor 1), which contains pyrrole, amide and amino subunits. This receptor shows both changes in its UV–vis absorption and fluorescence
- advantageous to develop high-effective sensors that can detect fluoride anion in food and animal feed. In this work, we report a new fluoride receptor 1 (Figure 1), 3-amino-5-(4,5,6,7-tetrahydro-1H-indol-2-yl)isoxazole-4-carboxamide [9], which contains receptive groups toward anions and no urea/thiourea
Graphical Abstract
Figure 1: (a) Receptor 1. (b) ORTEP drawing of receptor 1. Thermal ellipsoids are drawn at the 30% probabilit...
Figure 2: The absorption spectra of receptor 1 (5 μM) in the absence or presence of a 50 equiv of F−, Cl−, Br−...
Figure 3: The fluorescence spectra of receptor 1 (5 μM) in the absence or presence of a 50 equiv of F−, Cl−, ...
Figure 4: Comparison of fluorescence emission of 1 (5 μM) in CH3CN after the addition of 50 equiv of tetrabut...
Figure 5: UV–vis absorption changes of 1 (5 μM) upon the addition of TBAF in CH3CN.
Figure 6: Fluorescence emission changes of 1 (5 μM) upon the addition of TBAF in CH3CN (excited at 340 nm).
Figure 7: The fit of the experimental data of fluorescence emission of 1 (5 μM) upon the addition of F− at 40...
Figure 8: Fluorescence emission changes of 1 (5 μM) upon the addition of F− and OH− (5 equiv) in CH3CN (excit...
Figure 9: Partial 1H NMR (400 MHz) spectra of receptor 1 in the presence of 0, 0.2, 0.6, 1.0, 1.4, 1.6, 2.0, ...
Figure 10: Anionic form a and b of receptor 1.
Oxalyl retro-peptide gelators. Synthesis, gelation properties and stereochemical effects
- Janja Makarević,
- Milan Jokić,
- Leo Frkanec,
- Vesna Čaplar,
- Nataša Šijaković Vujičić and
- Mladen Žinić
Beilstein J. Org. Chem. 2010, 6, 945–959, doi:10.3762/bjoc.6.106
- carboxylic acid, methyl ester and carboxamide, namely (S,S)-bis(LeuLeu) 1a, b, c; (S,S)-bis(PhgPhg) 3a, b, c and (S,S)-bis(PhePhe) 5a, b, c and, the second containing two different amino acids, (S,S)-bis(LeuPhg) 2a, b, c and (S,S)-bis(PhgLeu) 4a, b, c (configurations of only two of the four stereogenic
- additional examples that some racemates could be more effective gelators of specific solvents than the pure enantiomers; (iii) among the terminal carboxamide gelators the heterochiral (S,R)-1c diastereoisomer is capable of immobilizing up to 10 and 4 times larger volumes of dichloromethane and toluene
Graphical Abstract
Scheme 1: Oxalyl retro-dipetide gelators; each b to a, (a) LiOH/MeOH, H2O; (b) H+; each b to c: (c) NH3/MeOH.
Figure 1: Chiral bis(amino acid)-(I) and bis(amino alcohol)-(II)-oxalamide gelators.
Figure 2: TEM images (PWK staining) of: (S,S)-1a H2O/DMSO gel.
Figure 3: TEM images (PWK staining) of: (S,R)-1a H2O/DMSO gel.
Figure 4: TEM images (PWK staining) of: (S,R)-1b toluene gel showing the presence of short tape like aggregat...
Figure 5: The concentration dependence of NH and C*H chemical shifts in (S,R)-1b toluene-d8 gel samples (conc...
Figure 6: The concentration dependence of NH and C*H chemical shifts in (S,S)-1b and its racemate (S,S)-1b/(R...
Figure 7: Temperature dependence of: a) oxalamide NH protons (▲), Leu-NH protons (Δ) and b) oxalamide-α-Leu-C...
Figure 8: Temperature dependent CD spectra of: a) (S,R)-1b decalin gel (c = 3.4·10−2 M); b) (S,S)-1b decalin ...
Figure 9: X-ray powder diffractograms of (a) (S,R)-1b and (b) (S,S)-1b xerogels prepared from their toluene g...
Figure 10: (a) Fully minimized the lowest energy conformations of (S,S)-1b (top) and (S,R)-1b generated by sys...
Figure 11: Schematic presentation of the proposed (S,S)-1b and (S,R)-1b basic packing model based on XRPD, 1H ...
Figure 12: X-ray powder diffraction (XRPD) diagram of (S,R)-1a water/DMSO xerogel.
Molecular recognition of organic ammonium ions in solution using synthetic receptors
- Andreas Späth and
- Burkhard König
Beilstein J. Org. Chem. 2010, 6, No. 32, doi:10.3762/bjoc.6.32
Graphical Abstract
Figure 1: Biologically important amines and quaternary ammonium salts: histamine (1), dopamine (2) and acetyl...
Figure 2: Crown ether 18-crown-6.
Figure 3: Conformations of 18-crown-6 (4) in solvents of different polarity.
Figure 4: Binding topologies of the ammonium ion depending on the crown ring size.
Figure 5: A “pseudorotaxane” structure consisting of 24-crown-8 and a secondary ammonium ion (5); R = Ph.
Figure 6: Typical examples of azacrown ethers, cryptands and related aza macrocycles.
Figure 7: Binding of ammonium to azacrown ethers and cryptands [111-113].
Figure 8: A 19-crown-6-ether with decalino blocking groups (11) and a thiazole-dibenzo-18-crown-6-ether (12).
Figure 9: 1,3-Bis(6-oxopyridazin-1-yl)propane derivatives 13 and 14 by Campayo et al.
Figure 10: Fluorescent azacrown-PET-sensors based on coumarin.
Figure 11: Two different pyridino-cryptands (17 and 18) compared to a pyridino-crown (19); chiral ammonium ion...
Figure 12: Pyridino-18-crown-6 ligand (21), a similar acridino-18-crown-6 ligand (22) and a structurally relat...
Figure 13: Ciral pyridine-azacrown ether receptors 24.
Figure 14: Chiral 15-crown-5 receptors 26 and an analogue 18-crown-6 ligand 27 derived from amino alcohols.
Figure 15: C2-symmetric chiral 18-crown-6 amino alcohol derivatives 28 and related macrocycles.
Figure 16: Macrocycles with diamide-diester groups (30).
Figure 17: C2-symmetric chiral aza-18-crown-6 ethers (31) with phenethylamine residues.
Figure 18: Chiral C-pivot p-methoxy-phenoxy-lariat ethers.
Figure 19: Chiral lariat crown ether 34.
Figure 20: Sucrose-based chiral crown ether receptors 36.
Figure 21: Permethylated fructooligosaccharide 37 showing induced-fit chiral recognition.
Figure 22: Biphenanthryl-18-crown-6 derivative 38.
Figure 23: Chiral lariat crown ethers derived from binol by Fuji et al.
Figure 24: Chiral phenolic crown ether 41 with “aryl chiral barriers” and guest amines.
Figure 25: Chiral bis-crown receptor 43 with a meso-ternaphthalene backbone.
Figure 26: Chromogenic pH-dependent bis-crown chemosensor 44 for diamines.
Figure 27: Triamine guests for binding to receptor 44.
Figure 28: Chiral bis-crown phenolphthalein chemosensors 46.
Figure 29: Crown ether amino acid 47.
Figure 30: Luminescent receptor 48 for bis-alkylammonium guests.
Figure 31: Luminescent CEAA (49a), a bis-CEAA receptor for amino acids (49b) and the structure of lysine bindi...
Figure 32: Luminescent CEAA tripeptide for binding small peptides.
Figure 33: Bis crown ether 51a self assembles co-operatively with C60-ammonium ion 51b.
Figure 34: Triptycene-based macrotricyclic dibenzo-[24]-crown-8 ether host 52 and guests.
Figure 35: Copper imido diacetic acid azacrown receptor 53a and the suggested His-Lys binding motif; a copper ...
Figure 36: Urea (54) and thiourea (55) benzo crown receptor for transport and extraction of amino acids.
Figure 37: Crown pyryliums ion receptors 56 for amino acids.
Figure 38: Ditopic sulfonamide bridged crown ether receptor 57.
Figure 39: Luminescent peptide receptor 58.
Figure 40: Luminescent receptor 59 for the detection of D-glucosamine hydrochloride in water/ethanol and lumin...
Figure 41: Guanidinium azacrown receptor 61 for simple amino acids and ditopic receptor 62 with crown ether an...
Figure 42: Chiral bicyclic guanidinium azacrown receptor 63 and similar receptor 64 for the enantioselective t...
Figure 43: Receptors for zwitterionic species based on luminescent CEAAs.
Figure 44: 1,10-Azacrown ethers with sugar podand arms and the anticancer agent busulfan.
Figure 45: Benzo-18-crown-6 modified β-cyclodextrin 69 and β-cyclodextrin functionalized with diaza-18-crown-6...
Figure 46: Receptors for colorimetric detection of primary and secondary ammonium ions.
Figure 47: Porphyrine-crown-receptors 72.
Figure 48: Porphyrin-crown ether conjugate 73 and fullerene-ammonium ion guest 74.
Figure 49: Calix[4]arene (75a), homooxocalix[4]arene (75b) and resorcin[4]arene (75c) compared (R = H, alkyl c...
Figure 50: Calix[4]arene and ammonium ion guest (R = H, alkyl, OAcyl etc.), possible binding sites; A: co-ordi...
Figure 51: Typical guests for studies with calixarenes and related molecules.
Figure 52: Lower rim modified p-tert-butylcalix[5]arenes 82.
Figure 53: The first example of a water soluble calixarene.
Figure 54: Sulfonated water soluble calix[n]arenes that bind ammonium ions.
Figure 55: Displacement assay for acetylcholine (3) with a sulfonato-calix[6]arene (84b).
Figure 56: Amino acid inclusion in p-sulfonatocalix[4]arene (84a).
Figure 57: Calixarene receptor family 86 with upper and lower rim functionalization.
Figure 58: Calix[6]arenes 87 with one carboxylic acid functionality.
Figure 59: Sulfonated calix[n]arenes with mono-substitution at the lower rim systematically studied on their r...
Figure 60: Cyclotetrachromotropylene host (91) and its binding to lysine (81c).
Figure 61: Calixarenes 92 and 93 with phosphonic acids groups.
Figure 62: Calix[4]arene tetraphosphonic acid (94a) and a double bridged analogue (94b).
Figure 63: Calix[4]arene tetraphosphonic acid ester (92c) for surface recognition experiments.
Figure 64: Calixarene receptors 95 with α-aminophosphonate groups.
Figure 65: A bridged homocalix[3]arene 95 and a distally bridged homocalix[4]crown 96.
Figure 66: Homocalix[3]arene ammonium ion receptor 97a and the Reichardt’s dye (97b) for colorimetric assays.
Figure 67: Chromogenic diazo-bridged calix[4]arene 98.
Figure 68: Calixarene receptor 99 by Huang et al.
Figure 69: Calixarenes 100 reported by Parisi et al.
Figure 70: Guest molecules for inclusion in calixarenes 100: DAP × 2 HCl (101a), APA (101b) and Lys-OMe × 2 HC...
Figure 71: Different N-linked peptido-calixarenes open and with glycol chain bridges.
Figure 72: (S)-1,1′-Bi-2-naphthol calixarene derivative 104 published by Kubo et al.
Figure 73: A chiral ammonium-ion receptor 105 based on the calix[4]arene skeleton.
Figure 74: R-/S-phenylalaninol functionalized calix[6]arenes 106a and 106b.
Figure 75: Capped homocalix[3]arene ammonium ion receptor 107.
Figure 76: Two C3 symmetric capped calix[6]arenes 108 and 109.
Figure 77: Phosphorous-containing rigidified calix[6]arene 110.
Figure 78: Calix[6]azacryptand 111.
Figure 79: Further substituted calix[6]azacryptands 112.
Figure 80: Resorcin[4]arene (75c) and the cavitands (113).
Figure 81: Tetrasulfonatomethylcalix[4]resorcinarene (114).
Figure 82: Resorcin[4]arenes (115a/b) and pyrogallo[4]arenes (115c, 116).
Figure 83: Displacement assay for acetylcholine (3) with tetracyanoresorcin[4]arene (117).
Figure 84: Tetramethoxy resorcinarene mono-crown-5 (118).
Figure 85: Components of a resorcinarene based displacement assay for ammonium ions.
Figure 86: Chiral basket resorcin[4]arenas 121.
Figure 87: Resorcinarenes with deeper cavitand structure (122).
Figure 88: Resorcinarene with partially open deeper cavitand structure (123).
Figure 89: Water-stabilized deep cavitands with partially structure (124, 125).
Figure 90: Charged cavitands 126 for tetralkylammonium ions.
Figure 91: Ditopic calix[4]arene receptor 127 capped with glycol chains.
Figure 92: A calix[5]arene dimer for diammonium salt recognition.
Figure 93: Calixarene parts 92c and 129 for the formation molecular capsules.
Figure 94: Encapsulation of a quaternary ammonium cation by two resorcin[4]arene molecules (NMe4+@[75c]2 × Cl−...
Figure 95: Encapsulation of a quaternary ammonium cation by six resorcin[4]arene molecules (NMe3D+@[130]6 × Cl−...
Figure 96: Structure and schematic of cucurbit[6]uril (CB[6], 131a).
Figure 97: Cyclohexanocucurbit[6]uril (CB′[6], 132) and the guest molecule spermine (133).
Figure 98: α,α,δ,δ-Tetramethylcucurbit[6]uril (134).
Figure 99: Structure of the cucurbituril-phthalhydrazide analogue 135.
Figure 100: Organic cavities for the displacement assay for amine differentiation.
Figure 101: Displacement assay methodology for diammonium- and related guests involving cucurbiturils and some ...
Figure 102: Nor-seco-Cucurbituril (±)-bis-ns-CB[6] (140) and guest molecules.
Figure 103: The cucurbit[6]uril based complexes 141 for chiral discrimination.
Figure 104: Cucurbit[7]uril (131c) and its ferrocene guests (142) opposed.
Figure 105: Cucurbit[7]uril (131c) guest inclusion and representative guests.
Figure 106: Cucurbit[7]uril (131c) binding to succinylcholine (145) and different bis-ammonium and bis-phosphon...
Figure 107: Paraquat-cucurbit[8]uril complex 149.
Figure 108: Gluconuril-based ammonium receptors 150.
Figure 109: Examples of clefts (151a), tweezers (151b, 151c, 151d) and clips (151e).
Figure 110: Kemp’s triacid (152a), on example of Rebek’s receptors (152b) and guests.
Figure 111: Amino acid receptor (154) by Rebek et al.
Figure 112: Hexagonal lattice designed hosts by Bell et al.
Figure 113: Bell’s amidinium receptor (156) and the amidinium ion (157).
Figure 114: Aromatic phosphonic acids.
Figure 115: Xylene phosphonates 159 and 160a/b for recognition of amines and amino alcohols.
Figure 116: Bisphosphonate recognition motif 161 for a colorimetric assay with alizarin complexone (163) for ca...
Figure 117: Bisphosphonate/phosphate clip 164 and bisphosphonate cleft 165.
Figure 118: N-Methylpyrazine 166a, N-methylnicotinamide iodide (166b) and NAD+ (166c).
Figure 119: Bisphosphate cavitands.
Figure 120: Bisphosphonate 167 of Schrader and Finocchiaro.
Figure 121: Tweezer 168 for noradrenaline (80b).
Figure 122: Different tripods and heparin (170).
Figure 123: Squaramide based receptors 172.
Figure 124: Cage like NH4+ receptor 173 of Kim et al.
Figure 125: Ammonium receptors 174 of Chin et al.
Figure 126: 2-Oxazolin-based ammonium receptors 175a–d and 176 by Ahn et al.
Figure 127: Racemic guest molecules 177.
Figure 128: Tripods based on a imidazole containing macrocycle (178) and the guest molecules employed in the st...
Figure 129: Ammonium ion receptor 180.
Figure 130: Tetraoxa[3.3.3.3]paracyclophanes 181 and a cyclophanic tetraester (182).
Figure 131: Peptidic bridged paraquat-cyclophane.
Figure 132: Shape-selective noradrenaline host.
Figure 133: Receptor 185 for binding of noradrenaline on surface layers from Schrader et al.
Figure 134: Tetraphosphonate receptor for binding of noradrenaline.
Figure 135: Tetraphosphonate 187 of Schrader and Finocchiaro.
Figure 136: Zinc-Porphyrin ammonium-ion receptors 188 and 189 of Mizutani et al.
Figure 137: Zinc porphyrin receptor 190.
Figure 138: Zinc porphyrin receptors 191 capable of amino acid binding.
Figure 139: Zinc-porphyrins with amino acid side chains for stereoinduction.
Figure 140: Bis-zinc-bis-porphyrin based on Tröger’s base 193.
Figure 141: BINAP-zinc-prophyrin derivative 194 and it’s guests.
Figure 142: Bisaryl-linked-zinc-porphyrin receptors.
Figure 143: Bis-zinc-porphyrin 199 for diamine recognition and guests.
Figure 144: Bis-zinc-porphyrin crown ether 201.
Figure 145: Bis-zinc-porphyrin 202 for stereodiscrimination (L = large substituent; S = small substituent).
Figure 146: Bis-zinc-porphyrin[3]rotaxane and its copper complex and guests.
Figure 147: Dien-bipyridyl ligand 206 for co-ordination of two metal atoms.
Figure 148: The ligand and corresponding tetradentate co-complex 207 serving as enantioselective receptor for a...
Figure 149: Bis(oxazoline)–copper(II) complex 208 for the recognition of amino acids in aqueous solution.
Figure 150: Zinc-salen-complexes 209 for the recognition tertiary amines.
Figure 151: Bis(oxazoline)–copper(II) 211 for the recognition of amino acids in aqueous solution.
Figure 152: Zn(II)-complex of a C2 terpyridine crown ether.
Figure 153: Displacement assay and receptor for aspartate over glutamate.
Figure 154: Chiral complex 214 for a colorimetric displacement assay for amino acids.
Figure 155: Metal complex receptor 215 with tripeptide side arms.
Figure 156: A sandwich complex 216 and its displaceable dye 217.
Figure 157: Lanthanide complexes 218–220 for amino acid recognition.
Figure 158: Nonactin (221), valinomycin (222) and vancomycin (223).
Figure 159: Monesin (224a) and a chiral analogue for enantiodiscrimination of ammonium guests (224b).
Figure 160: Chiral podands (226) compared to pentaglyme-dimethylether (225) and 18-crown-6 (4).
Figure 161: Lasalocid A (228).
Figure 162: Lasalocid derivatives (230) of Sessler et al.
Figure 163: The Coporphyrin I tetraanion (231).
Figure 164: Linear and cyclic peptides for ammonium ion recognition.
Figure 165: Cyclic and bicyclic depsipeptides for ammonium ion recognition.
Figure 166: α-Cyclodextrin (136a) and novocaine (236).
Figure 167: Helical diol receptor 237 by Reetz and Sostmann.
Figure 168: Ammonium binding spherand by Cram et al. (238a) and the cyclic[6]metaphenylacetylene 238b in compar...
Figure 169: Receptor for peptide backbone and ammonium binding (239).
Figure 170: Anion sensor principle with 3-hydroxy-2-naphthanilide of Jiang et al.
Figure 171: 7-bromo-3-hydroxy-N-(2-hydroxyphenyl)naphthalene 2-carboxamide (241) and its amine binding.
Figure 172: Naturally occurring catechins with affinity to quaternary ammonium ions.
Figure 173: Spiropyran (244) and merocyanine form (244a) of the amino acid receptors of Fuji et al.
Figure 174: Coumarin aldehyde (245) and its iminium species with amino acid bound (245a) by Glass et al.
Figure 175: Coumarin aldehyde appended with boronic acid.
Figure 176: Quinolone aldehyde dimers by Glass et al.
Figure 177: Chromogenic ammonium ion receptors with trifluoroacetophenone recognition motifs.
Figure 178: Chromogenic ammonium ion receptor with trifluoroacetophenone recognition motif bound on different m...
An enantiomerically pure siderophore type ligand for the diastereoselective 1 : 1 complexation of lanthanide(III) ions
- Markus Albrecht,
- Olga Osetska,
- Thomas Abel,
- Gebhard Haberhauer and
- Eva Ziegler
Beilstein J. Org. Chem. 2009, 5, No. 78, doi:10.3762/bjoc.5.78
- -carboxamide) 1a-H3 The ether 4 (0.18 g, 0.13 mmol) was placed in a Schlenk flask. The rearrangement proceeded at 165 °C under dry inert atmosphere of N2. The dark brown residue was purified by a short silica column (EtOAc, Rf = 0.26) to furnish a bright brown solid. Yield: 0.16 g (90 %); mp 189–196 °C. 1H NMR
- (m), 848 (s), 809 (w), 774 (m), 723 (m), 662 (w). HRMS (ESI): calcd. for C81H99N15O9 [M + Na]+: m/z = 1448.7619; found 1448.7637. Synthesis and characterization of a mononuclear lanthanum(III) complex with cyclohexapeptide based tris(N,N-diethyl-8-hydroxyquinoline-2-carboxamide) [(1a)La] LaCl3 · 7
Graphical Abstract
Figure 1: Structural formula of the siderophore enterobactine.
Scheme 1: Preparation of the compound 1a-H3 by utilization of a multiple Claisen-rearrangement.
Figure 2: 1H NMR spectra (300 MHz, CDCl3) of the ether compound 4 (top) and the ligand 1a-H3 (bottom).
Figure 3: Positive ESI MS of [(1a)La] in chloroform showing the peaks of {K[(1a)La]}+ (m/z = 1600.8) as well ...
Figure 4: CD and UV absorption titration curves for complexation of ligand 1a-H3 with lanthanum(III)nitrate h...
Figure 5: Titration curve observed for ligand 1a-H3 upon addition of lanthanum(III) nitrate hexahydrate.
Figure 6: Molecular structures of the Λ2 (left) and Δ2 (right) isomers of complex 1b·La calculated by using B...
Figure 7: UV and CD spectra of the complex (Λ)-1·La. Blue and violet curve: experimentally determined spectra...
Dipyridodiazepinone derivatives; synthesis and anti HIV-1 activity
- Nisachon Khunnawutmanotham,
- Nitirat Chimnoi,
- Arunee Thitithanyanont,
- Patchreenart Saparpakorn,
- Kiattawee Choowongkomon,
- Pornpan Pungpo,
- Supa Hannongbua and
- Supanna Techasakul
Beilstein J. Org. Chem. 2009, 5, No. 36, doi:10.3762/bjoc.5.36
- . Then amine 27 and the acid 30 underwent coupling to produce carboxamide 31. Diazepinone ring closure was performed by heating 31 in hexamethyldisilazane. Afterwards, the nitro group was reduced to produce the hydrochloride salt 10. Treatment of 10 with 50% aqueous NaOH yielded its corresponding free
Graphical Abstract
Figure 1: Structure of nevirapine (1).
Figure 2: Structures of dipyridodiazepinone derivatives with promising anti-HIV activity.
Scheme 1: Reagents and conditions: (a) EtNH2, 120 °C, 4 h, 99% (b) i) (COCl)2, benzene, DMF, rt, 1 h; ii) ami...
Scheme 2: Reagents and conditions: (a) Br2, HOAc, KOAc, rt, 1 h; (b) NaHMDS, pyridine, 90 °C, 1 h; (c) CH2=CH...
Scheme 3: Reagents and conditions: (a) POCl3, 150 °C, 6 h, 85%; (b) cyclopropylamine, xylene, 105 °C, 4 h, 99...
Figure 3: Docked orientations of nevirapine (green), 9 (yellow), 5, and 6 (atom type color – carbon: grey, ch...
Synthesis of rigidified flavin–guanidinium ion conjugates and investigation of their photocatalytic properties
- Harald Schmaderer,
- Mouchumi Bhuyan and
- Burkhard König
Beilstein J. Org. Chem. 2009, 5, No. 26, doi:10.3762/bjoc.5.26
- -dihydrobenzo[g]pteridin-10(2H)-yl]ethyl}-3-azabicyclo[3.3.1]nonane-7-carboxamide; Flavin-Boc-guanidin 7 To a solution of HOBt·H2O (89 mg, 580 μmol), EDC (90 mg, 580 μmol) and DIPEA (171 μL, 970 μmol) in CH2Cl2 (6.5 mL) were added compound 6 (252 mg, 480 μmol) and mono Boc-protected guanidine (86 mg, 530 μmol
- -7-carboxamide; Flavin-Boc-guanidin 10 To a solution of HOBt·H2O (226 mg, 1.67 mmol), EDC (226 mg, 1.45 mmol) and DIPEA (498 μL, 970 μmol) in CHCl3 (10 mL) was added compound 9 (548 mg, 969 μmol) and mono Boc-protected guanidine (231 mg, 1.45 mmol) at 0 °C. The mixture was stirred at room temperature
- -azabicyclo[3.3.1]nonane-7-carboxamide; Flavin-guanidinium 1 Compound 7 (210 mg, 317 μmol) was dissolved in CHCl3 (25 mL) and hydrogen chloride saturated diethyl ether (3 mL) was added dropwise. After stirring for 24 h, the solution was evaporated to 5 mL and diethyl ether (15 mL) was added to precipitate the
Graphical Abstract
Scheme 1: Flavin–guanidinium ion conjugates 1 and 2 and tetraacetyl riboflavin (3).
Scheme 2: Synthesis of flavins 1 and 2. Conditions: (i) DMAP, H2O, Δ, 20 h, 71–78%, (ii) HOBt, EDC, NEt(iPr)2...
Figure 1: X-ray crystal structures of the flavin-Kemp’s acids 6 (left) and 9 (right).
Figure 2: Structure of compound 1 in the solid state.
Figure 3: Calculated lowest energy conformation of 1 in the gas phase (AM1, Spartan program package).
Scheme 3: Oxidative photocleavage of dibenzyl phosphate.
Scheme 4: Photoreduction of 4-nitrophenyl phosphate.
Scheme 5: Photo Diels–Alder-reaction of anthracene with N-methyl-maleinimide.
Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine- 2-carbonitrile: A key intermediate for dipeptidyl peptidase IV inhibitors
- Santosh K. Singh,
- Narendra Manne and
- Manojit Pal
Beilstein J. Org. Chem. 2008, 4, No. 20, doi:10.3762/bjoc.4.20
- , 166.1, 166.4, 174.8, 174.9; m/z 192.1 [M+1]; Anal. Calcd for C7H10ClNO3: C, 43.88; H, 5.26; N, 7.31. Found: C, 43.25; H, 4.91; N, 6.98. Preparation of (S) 1-(2-chloroacetyl)pyrrolidine-2-carboxamide (9) To a solution of compound 8 (10.0 g, 0.052 mol) in dichloromethane (200 mL) was added slowly a
Graphical Abstract
Figure 1: DPP-IV Inhibitors.
Figure 2: Role of 2(S)-cyanopyrrolidine moiety in DPP-IV inhibition.
Scheme 1: Earlier route to (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile (6).
Scheme 2: Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile (6).
Scheme 3: Preparation of Vildagliptin (2).
